Skip to main content


  • Meeting abstract
  • Open Access

Integrase inhibitors effective against human T-cell leukemia virus type 1

Retrovirology20118 (Suppl 1) :A34

  • Published:


  • Human Immunodeficiency Virus
  • Peripheral Blood Mononuclear Cell
  • Human Peripheral Blood
  • Human Peripheral Blood Mononuclear Cell
  • Associate Disease

Drugs targeting the viral enzyme integrase have been in use for several years as part of the treatment regimen for patients with Human Immunodeficiency Virus Type 1 (HIV-1) and similar classes of compounds have been shown to inhibit Human T-Cell Leukemia Virus Type 1 (HTLV-1) integration in vitro. The current study shows that the clinically approved HIV-1 integrase inhibitor, Raltegravir, as well as the more recent diketo acid derivative, MK-2048, are active inhibitors of HTLV-1 infection in vitro. These agents were effective in inhibiting cell-free and cell-to-cell transmission of HTLV-1 in lymphoid and non-lymphoid cells. The drugs also inhibited HTLV-1 immortalization of human peripheral blood mononuclear cells. A novel adaptation of the Alu assay for viral integration was used to show that the drugs inhibit viral integration without affecting reverse transcription. These data support the administration of Raltegravir and other integrase inhibitors as treatments for patients with HTLV-1 associated diseases.

Authors’ Affiliations

Division of Molecular Oncology, Washington University, St Louis, MO 63110, USA


© Seegulam and Ratner; licensee BioMed Central Ltd. 2011

This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.